

SPEAKER: Well, there are still barriers in using PCSK9 monoclonal antibodies. Many of the cardiologists in my community are starting them. But a number of people do not feel comfortable with them, have had problems prescribing them. And there are the barriers involved-- being able to get through the prior authorization and being able to make a good case for the PCSK9.

I think that if the patient fulfills the indications in the package insert, they are not at goal, they're still very high LDL, then I don't think it's a big issue about whether or not to make the decision. The question is getting it done. And that is not always easy. It requires a lot of time and effort in some cases. In the US, the barriers with regard to the pharmacy benefits providers can be quite significant, and it can be quite frustrating.